P650: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BTK DEGRADER, IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL MALIGNANCIES

• K. Linton,
• G. P. Collins,
• D. El-Sharkawi,
• R. Mous,
• F. Forconi,
• M. Tan,
• S. Nandakumar,
• E. Meredith,
• K. L. Jameson,
• S. G. Injac,
• J. Doorduijn

Affiliations

K. Linton

1 The University of Manchester, Manschester

G. P. Collins

2 Oxford University Hospitals NHS Trust, Oxford

D. El-Sharkawi

3 Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

R. Mous

4 UMC Utrecht Cancer Center, University Medical Center, Utrecht, Netherlands

F. Forconi

5 University Hospital Southampton NHS Trust, Southhampton, United Kingdom

M. Tan

6 Nurix Therapeutics, Inc., San Francisco, United States of America

S. Nandakumar

6 Nurix Therapeutics, Inc., San Francisco, United States of America

E. Meredith

6 Nurix Therapeutics, Inc., San Francisco, United States of America

K. L. Jameson

6 Nurix Therapeutics, Inc., San Francisco, United States of America

S. G. Injac

6 Nurix Therapeutics, Inc., San Francisco, United States of America

J. Doorduijn

7 Erasmus MC Cancer Institute, Rotterdam, Netherlands